CurcumPedALL: Safety and Efficacy of Curcumin in Children With Acute Lymphoblastic Leukemia
Study Details
Study Description
Brief Summary
Assessment of of the biological effects of curcumin on microbiota in children with acute lymphoblastic leukemia
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2 |
Detailed Description
Assessment of the safety of curcumin, which is the most active constituent of the ground rhizome of the Curcuma longa plant, in children with acute lymphoblastic leukemia patients (ALL) in maintenance phase of chemotherapy through the assessment of the any reported adverse event (AE). And assessment of the curcumin effect on health by eliminating intestinal microflora dysbiosis
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Active Comparator: Curcumin Tumeric curcumin 500 mg per oral capsule of Puritans Pride company supplement (composed of Tumeric (curcuma longa)root 450mg and Tumeric extract (curcuma longa )root 50mg ) standardized to contain 95%curcuminoids, it will given twice daily for 1 month starting at week 1 of maintenance phase of chemotherapy (Time 1) . It is preferably to be taken with meals but may be opened and prepared as a tea |
Drug: Curcumin
Tumeric curcumin 500 mg per oral capsule of Puritans Pride company supplement
Other Names:
Dietary Supplement: Standard of Care
As per institution protocol for Standard of nutritional Care
|
Placebo Comparator: Standard of nutritional care Standard of nutritional support care |
Dietary Supplement: Standard of Care
As per institution protocol for Standard of nutritional Care
|
Outcome Measures
Primary Outcome Measures
- Determine the Safety of curcumin in pediatric patients with ALL. [4 weeks]
Percentage of patients who developed adverse event
Eligibility Criteria
Criteria
Inclusion Criteria:
Children aged from 1 year to 18 years Children with proven ALL diagnosed by bone marrow aspirate and immunephenotyping Patients in the maintenance phase week1
Exclusion Criteria:
Children with other maliganacies, Current use (past use of these medications is not an exclusion) of medications or over-the-counter treatments including to sulfasalazine, warfarin, clopidogrel, aspirin, antacids, botanical treatments (ginger, feverfew, yellow clover, Salix species, Populus species, Betula species, and Gaultheria species), essential fatty acids (flax oil and fish oil).
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Pediatric Hematology Oncology and BMT Unit, Faculty of Medicine Ain Shams University | Cairo | Non-US | Egypt | 11566 |
Sponsors and Collaborators
- Ain Shams University
Investigators
- Study Chair: Ihab Khairy, M.D, Faculty of Medicine Ain Shams University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- FMASU MD 134/2021